

# PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH VOLUME 1

---

---

## CONTENTS

<b>Preface</b>	<i>Irving J. Pflug</i>	<b>xi</b>
<b>Introduction</b>	<i>Jack Lysfjord</i>	<b>xv</b>
<b>Acknowledgements</b>		<b>vxxii</b>
<b>Dedication</b>		<b>xix</b>
<b>Glossary</b>		<b>xxi</b>
 <b>Part One: Current Global Influences on Aseptic Processing</b>		
<b>I</b>	<b>Regulatory Background to Aseptic Processing</b> <i>Richard Johnson and Gordon Farquharson</i>	<b>3</b>
	Introduction	3
	Global Regulatory Guidance	5
		<b>iii</b>

	US FDA	5
	EU Annex I	11
	Canadian Regulation	14
	Japanese Guidance	15
	Other Useful References	16
	Conclusion	17
	About the Authors	17
<b>2</b>	<b>Development Requirements of Biopharmaceutical Parenteral Dosage Forms</b>	<b>19</b>
	<i>John A. Bontempo</i>	
	Key Requirements to Consider Before Preformulations and Formulations of Biopharmaceuticals Begin	20
	Summary	32
	References	32
	About the Author	34
<b>3</b>	<b>Biopharmaceutical Therapeutics Dosage Forms Delivery Systems and Current Status of Extractables and Leachables in Respective Parenteral Dosage Forms</b>	<b>35</b>
	<i>John A. Bontempo</i>	
	Pre-filled Syringes	38
	Auto-injectors	43
	Pen Injector	45
	Needle-free Injectors	46
	Summary	46
	Current Status of Extractables and Leachables in Respective Dosage Forms	46
	What are Extractables and Leachables	47
	Rigid Needle Shield	51
	References	52
	About the Author	53
<b>4</b>	<b>Vaccines: Moving into the Future</b>	<b>55</b>
	<i>John Finkbohner</i>	
	Introduction	55
	Vaccines in the United States	56
	Use of Vaccines in the U.S.	63
	Overview of Immune Responses	63

Type of Vaccines	64
Challenges Facing the Modern Vaccine Business	66
Challenges of Vaccine Manufacturing	67
Formulation of Vaccines	71
Future Growth of Vaccines	74
Summary	76
References	77
About the Author	80

## Part Two: Current Aseptic Processing Techniques

<b>5</b>	<b>Container Preparation — Washing, Sterilization and Deyrogenation</b>	<b>85</b>
	<i>Johannes Rauschnabel, Patrizia Dittmer and Thomas Kosian</i>	
	Container Cleaning	86
	Sterilization and Deyrogenation with Dry Heat	93
	References	103
	About the Authors	103
<b>6</b>	<b>Vial Processing — Accumulating, Conveying, Filling and Stoppering the Most Common Parenteral Container</b>	<b>105</b>
	<i>Alan Peterson</i>	
	Introduction	105
	Vial Infeed	107
	Vial Transport — Intermittent Versus Continuous Motion	110
	Overall Vial Transport Design	115
	Vial Handling — Neck Vs. Bottom	117
	Dosing Systems — Introduction	119
	Product Contact	120
	Filling Needles (Nozzles)	120
	Product Considerations	122
	Product Supply and Special Handling	123
	CIP/SIP	125
	Stoppering	125
	Quality Control	131
	Summary	133
	About the Author	133

<b>7</b>	<b>Checkweighing Fill Weight of Parenteral Product is the Heart of Process Quality</b>	<b>135</b>
	<i>Alan Peterson</i>	
	Introduction	135
	Precision and Accuracy of Fill Volumes — Definitions and Statistical Analysis	136
	Checkweighing Methods	138
	Summary	144
	About the Author	144
<b>8</b>	<b>Filling Methods as they Apply to Parenteral Product Quality and Biopharmaceutical Microdosing</b>	<b>145</b>
	<i>Alan Peterson</i>	
	Introduction	145
	Time Pressure Filling	146
	Fill by Weight	149
	Mass Flow Filling	150
	Gravimetric Filling	153
	Peristaltic Pump Filling	156
	Piston Pumps	157
	Rolling Diaphragm Pump	161
	Microdosing	162
	Summary	165
	About the Author	165
<b>9</b>	<b>Disposables — Single-Use Systems for Aseptic Processing and Filling Operations</b>	<b>167</b>
	<i>Eric Isberg</i>	
	Background	167
	Use in Dosing Systems	170
	Materials of Construction	176
	Usage Considerations	177
	Materials Testing	178
	Sterility	179
	About the Author	180
<b>10</b>	<b>Parenteral Non-Vial Container Formats — Ampoules, Syringes, Cartridges, Ophthalmics and IV Bags</b>	<b>181</b>
	<i>Alan Peterson</i>	
	Introduction	181

	Ampoules	182
	Syringes	183
	Bulk Glass Syringes	183
	Syringe Filling and Stoppering	187
	Cartridges	189
	Nested Syringe Processing	189
	Plastic Syringes	191
	Ophthalmics — Plastic Bottles Dominate	193
	IV Bags	195
	Summary	195
	About the Author	197
<b>11</b>	<b>Application and Insights for Lyophilization of Parenteral Products</b>	<b>199</b>
	<i>Edward H. Trappler</i>	
	Introduction	199
	Applications of Lyophilization in Sterile Product Processing	201
	Unique Requirements of Lyophilized Products	202
	Characteristics of Lyophilized Parenterals	204
	Processing Steps	205
	Lyophilization Process Overview	205
	Freezing	207
	Primary Drying	209
	Secondary Drying	209
	Applications of Basic Principles	210
	Methods of Analysis	211
	Importance of the Phase Transition Temperature	211
	Examples of Freeze Drying Cycles	213
	Influences of Aseptic Process in Manufacturing	214
	Process Control Parameters	215
	Lyophilization Equipment	216
	References	228
	About the Author	229
<b>12</b>	<b>Today's Integration of the Lyophilizer — Automated Loading and Unloading</b>	<b>231</b>
	<i>Ernesto Renzi</i>	
	Introduction	231
	History	233
	Modern Loading/Unloading Systems	238
	Flexible Loading Systems	239

	Fixed Loading System	243
	Freeze Dryers Designed for Loading Systems	250
	Shelves	250
	Freeze Dryer Chamber	252
	Hydraulic Stoppering System	253
	Equipment Layout	255
	Conclusion	258
	About the Author	259
<b>13</b>	<b>Crimp Sealing Parenteral Vials</b>	<b>261</b>
	<i>F. William Bogle, Roger P. Asselta and Lawrence Pepper</i>	
	Determining Percent Compression of Rubber Stoppers and Correlation to RSF in Parenteral Vials	263
	Jaw Type Sealing	265
	Spinning Roller Designs	267
	Sealing Rail Cappers	269
	Monitoring of Sealing Forces	269
	Capping Environments	270
	Alternatives	271
	References	272
	About the Authors	273
<b>14</b>	<b>Inspection of Parenteral Products in Vials, Ampoules, Syringes and Cartridges</b>	<b>275</b>
	<i>Mike de la Montaigne, Pedro J. Méndez and Ryosaku Tagaya</i>	
	Introduction	275
	Manual, Semi-Automated, and Automated Inspection Methods	276
	Comparing the Quality, Economy and Efficiency of Inspection Methods	277
	Visual (Human) Inspection Systems	278
	Manual Inspection Systems	281
	Semi-automated Visual Inspection Systems	281
	Automated Inspection Systems	283
	Reflected Light (Camera-Based) Automated Inspection Systems	283
	Transmitted Light (Static Division) Automated Inspection Systems	284
	Static Division System Operation	287
	Static Division Sensor	287
	Sensing Capabilities	288
	Conveyance of Containers	289

	Fill Level Check	290
	Camera-based Systems for Particulate and Cosmetic Inspection	290
	Typical Areas of Inspection by Container Type	294
	Validation of Automated Inspection Systems	296
	Visual Observation Tool	300
	Summary	301
	References	302
	About the Authors	304
<b>15</b>	<b>New Inspection Developments</b>	<b>305</b>
	<i>James Veale</i>	
	Introduction	305
	Nondestructive Headspace Analysis	207
	Regulatory Issues and Perspective	309
	Laser Technology for Rapid and Nondestructive Headspace Analysis	313
	Headspace Inspection Systems	321
	Aseptic Processing Applications	336
	Conclusion	369
	References	370
	About the Author	372
<b>16</b>	<b>Practical Things to Improve Aseptic Process Equipment System Operation, Reduce Interventions and Reduce Product Risk</b>	<b>373</b>
	<i>Jack Lysford</i>	
	About the Author	386
<b>17</b>	<b>Dealing with the Complexities of Control Systems and Systems Integration</b>	<b>387</b>
	<i>Terrance G. Petro</i>	
	Introduction	387
	Description of the Isolated Fill Line	387
	Boundaries of the System	389
	Overall Scope Definition	390
	Requirements of the System	392
	Control Room Selection	392
	Synchronization of Equipment	393
	SCADA Communication	394

Machine Specific Control Issues	395
General Control Issues	396
Conclusion	398
About the Author	398

<b>Index</b>	<b>401</b>
--------------	------------



# PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH VOLUME 1

---

---

## PREFACE

**Irving J. Pflug**

The manufacturing isolator, as it is used in 2009, is the culmination of perhaps, 60 years of developments in the microbial control of the sterile products manufacturing environment.

Equipment developers Al Larson and Jack Lysfjord of TL Systems Corp. were forward-looking innovators, who in 1985 had a vision that they could install a manufacturing line in the already proven glove-box containment system. Working with Hans Melgaard of Despatch Industries Inc., an expert in HVAC and particulate control in air systems, they developed a system where containers were fed from a washer and continuous sterilization–depyrogenation tunnel directly into a fill finish isolator system where high efficiency particulate air (HEPA)-filtered air was used to pressurize the system.

The microbiology quality of injectible pharmaceutical products produced in the 1950s clean room was of continuous concern.

Knowledgeable operators recognized that the microbiological quality of the products produced in the 1950s clean room system was related to the human operators in the clean room — the human in the clean room was the source of the contamination. Control measures were taken, starting with gowns, hair coverings and masks, then a full bunny suit; however, the human was still in the clean room.

The leap forward in control was moving the barrier from the operator to the production line. Instead of putting coverings (bunny suit) on the individual and trying to contain the microorganisms within a bunny suit (to keep them from escaping to contaminate the manufacturing area), the barrier was placed around the production line with the human operator outside the enclosure or isolator. This was a positive, controllable approach to solving the problem of the microorganism shed by the human operators from contaminating the product being packaged.

The availability of air, essentially free of microbial contamination, is a critical component of the isolator system. Today the development of the HEPA filter, laminar/unidirectional flow clean room system is often taken for granted and assumed by the young to have always existed. This system was developed with the support of the National Aeronautical and Space Administration (NASA) for producing higher levels of quality in intricate space vehicles (basis for the important original U.S. Federal Standard 209 which has recently been superseded by ISO 14644), and is one of the more important and recent technological advances that has helped the pharmaceutical industry in many ways. The HEPA filtered clean air is a critical part of the manufacturing isolator system.

The isolator itself will prevent microbial ingress, however, a method of decontaminating the isolator is a basic requirement of the manufacturing isolator system. We have been able to sterilize biological material, media and hardware, primarily using saturated steam under pressure for 100 years. We have been using ethylene oxide (EO) for sterilization for 50 years. Neither of these agents is suited for the isolator. The isolator is a large enclosure, not readily suited for one atmosphere of over pressure, and it requires human operators to work intimately with the system. Hydrogen peroxide ( $H_2O_2$ ), an old chemical with many important attributes, has become the sterilant of choice for the manufacturing isolator system. We are surprised that, in recent years, it has not received very much attention in the microbial-control area. The oxidizing capacity of  $H_2O_2$  is so strong that the chemical is considered a highly reactive oxygen species. It is used extensively in the pulp and paper industry. The FDA has classified  $H_2O_2$  a low regulatory priority (LRP) drug. A 3% solution is sold as an over-the-counter drug and is used for cleaning wounds and as an oral debriding agent.

Hydrogen peroxide is used to decontaminate the manufacturing isolator in an air- $H_2O_2$  system or in an atmospheric steam- $H_2O_2$  system. In the atmospheric steam- $H_2O_2$  system at 100.0°C, the kill of *Geobacillus stearothermophilis* spores is faster than in saturated steam at 15 psi pressure and 121.1°C.

The pharmaceutical manufacturing isolator is an engineering system which is capable of high production rates of products with both high quality level and at a unit cost not heretofore possible. As pharmaceutical products become more

potent and more hazardous to healthy individuals, operators must be protected from harmful agents. Isolators are one of the best engineering solutions for protecting both the product *and* operator. This represents a giant leap forward from the manufacturing systems in use only 20 years ago.

# PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH VOLUME 1

---

---

## INTRODUCTION

Jack Lysfjord

The seed for this book was planted in September 2005 at the PDA/FDA meeting in Washington D.C. Amy Davis, publisher of this book, and I were discussing how aseptic processing had changed since the mid 1990s.

Regulations have certainly changed with ISO 14644 cleanroom standards, 2004 FDA Aseptic Processing Guidelines, revision of Annex 1 of EU GMPs and International Council on Harmonization (ICH) working toward better global alignment of regulatory issues between countries.

Aseptic processing technology had changed with the use of Advanced Aseptic Processing techniques, such as blow/fill/seal (BFS), isolators and Restricted Access Barrier Systems (RABS). I believe that the product contamination rate can be improved from 1 contaminated unit out of 1,000 with conventional cleanroom processing to 1 out of 1,000,000 or even 1 out of 10,000,000 with the proper use of these advanced aseptic processing techniques. Conventional cleanroom processing has an inherent risk of human operators shedding of particles with viable micro-organisms into the containers.

Validation philosophy has evolved with the 5th edition of Good Automated Manufacturing Practices (GAMP 5). It is truly better understood today by industry as well as regulators. Process Analytical Technology (PAT), Quality by Design (QbD) with ICH Q8 (pharmaceutical development), Q9 (risk assessment) and Q10 (quality systems) tying things together for a better controlled process.

**xv**

Products are changing with the increasing dominance of biologicals and biotech products including vaccines. Several large, well established pharmaceutical companies (over 100 years old) have now declared themselves to be “Biotech Companies”.

Today, more products are being produced that have a containment requirement, such as cytotoxics, to protect operators of process equipment and nurses who administer drugs to the patient.

Manufacturing of clinical trial material is a growing critical phase of aseptic processing as is the compounding of sterile preparations.

The rate of change is increasing rapidly. I felt as a contribution to newcomers to the industry, the seasoned person in operations, engineering or quality, pharmacists and regulators, that this book would draw a line in the sand for 2009 as to what is being done at this point in time. Current Good Manufacturing Practices (cGMP) are the current “state of the art”. We all need to stay on top of “what is current?”.

To limit the scope of this book, it will deal with manufacturing aseptic products until the container is closed, inspected and can be placed into “in process inventory” under quarantine. It will not deal with the downstream operations that involve “paper products” such as labeling, cartoning, casepacking etc.

I have worked hard to assemble a global group of authors for chapters that are experts in their particular topic to share their knowledge with you. I hope this information will be valuable for years to come.

Jack Lysfjord  
Lysfjord Consulting LLC

# PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH VOLUME 1

---

---

## ACKNOWLEDGEMENTS

I want to thank my bride of 41 years, Pat, for sharing our life's journey together and putting up with my numerous travels and idiosyncrasies in corporate life and now as an independent consultant officing at home.

I also want to thank these people who come to mind. Who were and are mentors for life:

- Larry McGrath, with business, strategic vision, motivation, planning and weaving fun into work strengths
- Jerry Potter, with a “business nose”, sales skills and having fun while working philosophy
- Some of the TL Systems “Old Timers” from the good old days
  - Alan Peterson, Terry Petro, Dale Enwiller, Steve Braunschweig, Steve Swanson, Mike Beel, Ted Jagger, Carl Larson and Fred Nungesser
- The godfather of microbiology, Irving J. Pflug, for his wisdom and knowledge
- The drivers for what became the BUGS and LUMs groups
  - Irving J. Pflug, University of Minnesota, Allan Larson, president, TL Systems and Hans Melgaard, VP Technology, Despatch Industries

**xvii**

- Bob Best, president, ISPE who took on the idea of barriers and isolators
- Two pharmacists who help me see through their eyes:
  - Berthold Duethorn and Tom Jeatran
- Some of the regulators who helped advance the technology of aseptic processing:
  - Terry Munson, Ken Muhvich, Peter Cooney, Bob Sausville and Rick Friedman

Life is a journey. Enjoy it! Live your Bliss!

Jack Lysfjord  
Minnetonka, Minnesota, March 10, 2009

# PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH VOLUME 1

---

---

## DEDICATION

I dedicate this book to the patients of the world! Everyone has been, is or will be a patient. I hope the contents of the book will positively influence the governments, regulators and the pharmaceutical and related industries to produce more, better, safer and more cost effective products to help patients lead a full productive life.